Two CEOs at the AHIP Institute and Expo 2017 conference focused on more affordable pharmaceuticals during a keynote presentation.
Harvard Pilgrim President and CEO Eric Schultz and Eli Lilly Chairman, President and CEO David Ricks talked about ways to shift pricing strategies to a more value-based solution.
“Now is the time for collaboration and innovation,” Ricks said. “(The United States spends) 18 percent of GDP on health care. EpiPen, Valeant … we get painted with that brush; that’s not helping us — it isn’t even our model. We would like that to go away.”
Schultz said value-based pricing is a move in the right direction, but added that savings tend to be more noticeable in high-priced drugs.
“[Savings are] very modest, but I do believe there’s an opportunity down the road,” Schultz said. “But right now, it’s about clinical outcomes.”